About ReBEC

The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more

Everything you need to know about ReBEC

Click to access the hotsite

Click to download the PDF version

Instructions for the Registrant

We recommend reading the Registrant's Manual.

1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password. 
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.

Clinical Research Volunteer

Would you like to become a volunteer in a clinical trial registered in ReBEC?

Access our FAQ to find out how.

10/30/2026  |  Gina Mauro/Coral O. Omene  |  Targeted One

https://www.targetedonc.com/view/why-black-women-are-underrepresented-in-breast-cancer-trials-and-what-dr-coral-omene-is-changing 

Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr Coral Omene on why.

Breast cancer does not kill equally. Across every racial and ethnic group in the United States, Black women die from breast cancer at rates up to 40% higher than their white counterparts. They are more likely to be diagnosed with triple-negative disease—the most aggressive subtype—and they are far more likely to face those odds without ever having been included in the research that produced the treatments being used to fight it.

Some FDA-approved drugs cleared trials where minority enrollment was under 2%. Others had 0 Latino patients. One had 5 Black patients total. These are not rounding errors. They are a design failure, and Coral Omene, MD, PhD, has been saying so publicly for years.

Omene is a breast medical oncologist and program director for Breast Cancer Disparities Research at Rutgers Cancer Institute in New Brunswick, New Jersey. She holds both her MD and PhD from Columbia University, runs breast cancer clinical trials as site PI for the iSPY 2 adaptive platform, and held a V Foundation grant, awarded in partnership with ESPN, specifically to increase clinical trial participation among Black women. Rutgers Cancer Institute, where she works, enrolls nearly 50% minority participants in clinical trials. She believes they may be the only institution in the country hitting that number.

On the latest episode of The Moonlight Shift, host Gina Mauro asked her what she does when a Black…

10/30/2026  |   Marisa Horak  |  Rare Cancer

https://rarecancernews.com/news/trial-finds-treatment-eases-pv-symptoms-despite-missing-main-goal/ 

Jakafi better than best available therapy at easing itching and fatigue

Early treatment with Jakafi (ruxolitinib) is no better than older therapies at inducing a complete response in those with polycythemia vera (PV), but it may be better at easing certain disease symptoms, according to results from a clinical trial.

The Phase 2 trial, called RuxoBEAT (NCT02577926), was sponsored by RWTH Aachen University in Germany. In the trial, 78 previously untreated adults with PV were randomly assigned to treatment with Jakafi or with best available therapy (BAT). The main goal was to see how many patients achieved a complete response — meaning blood cells were normalized, and patients reported no symptoms.

Results showed the study missed this goal: in patients given either Jakafi or BAT, less than 3% of patients experienced a complete response. But even though the study missed its main goal, secondary outcomes showed benefits with Jakafi relative to BAT.

Full results from the trial were published in Blood Cancer Journal, in the paper “Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.” The work was funded by Novartis, which markets Jakafi.

Jakafi outperformed BAT in reducing spleen enlargement
PV is a form of blood cancer marked by the overproduction of certain blood cells, which leads to issues including abnormal blood cell counts and an enlarged spleen. Jakafi is a cytoreductive therapy, meaning a treatment designed to lower blood cell counts. Currently, it is approved as a treatment for PV patients…

10/30/2026  |  LeAnne Gendreau/Katherine Ambrose/Sondra 'Sam' Cradduck/Amy Cameron O’Rourke/Dr. Rhea Rogers  |  KGNS News

https://www.kgns.tv/2026/10/30/what-look-clinical-trial-why-older-adults-should-be-included/ 

What to look for when choosing a study and deciding whether to participate

Clinical trials can be a proactive way to explore new treatments, but studies show older adults are often left out of them, even though many conditions affect older adults more often.

The Aging Untold experts hosts are discussing what to look for when choosing a study and how to decide whether to take part.

Start with the question the trial is trying to answer
Dr. Rhea Rogers, a board-certified physician, said the first step is to change the question you ask.

“I think the first thing we have to do is not think about, ‘Can this clinical trial help me?’ but ‘What is this clinical trial trying to answer?’” Rogers said. “That’s what most of these trials are about.”

A trial is not a last resort
Rogers said many people see clinical trials as a last resort.

“I think a lot of people think that it’s a last resort option, that you don’t have anything else, when in fact one of the biggest benefits is it gives you access,” Rogers said. “You get great access to tomorrow’s medicines today — devices, therapies and other things that will not be available to everybody else for years.”

Where to find a study
Rogers said people can search at ClinicalTrials.gov , check with their physician or look at academic centers and other organizations specific to a disease or condition that have their own studies.

What…